September 20, 2020 10:20 AM EDTUpdated 12:35 PM
R&D

#ES­MO20: It’s not just Keytru­da any­more — Mer­ck spot­lights 3 top ear­ly-stage can­cer drugs

John Carroll

Editor & Founder

Any $12 bil­lion megablock­buster in the port­fo­lio tends to over­shad­ow every­thing else in the pipeline. Which is some­thing Mer­ck can tell you a lit­tle bit …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times